Citadel Advisors
TMCI icon

Citadel Advisors’s Treace Medical Concepts TMCI Stock Holding History

Citadel Advisors’s Portfolio TMCI Stock Details TMCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-73,200
Closed -$179K – 14233
2025
Q4 		$179K Buy
+73,200
New +$318K ﹤0.01% 11124
2025
Q2 		– Sell
-3,000
Closed -$25.2K – 15088
2025
Q1 		$25.2K Sell
3,000
-6,100
-67% -$54.8K ﹤0.01% 12969
2024
Q4 		$67.7K Sell
9,100
-122,300
-93% -$818K ﹤0.01% 12020
2024
Q3 		$762K Buy
131,400
+5,400
+4% +$34.7K ﹤0.01% 7383
2024
Q2 		$838K Buy
126,000
+111,900
+794% +$904K ﹤0.01% 6962
2024
Q1 		$184K Sell
14,100
-11,800
-46% -$157K ﹤0.01% 10445
2023
Q4 		$330K Buy
25,900
+10,000
+63% +$101K ﹤0.01% 8976
2023
Q3 		$208K Buy
+15,900
New +$291K ﹤0.01% 9826
2023
Q2 		– Sell
-23,800
Closed -$600K – 15241
2023
Q1 		$600K Buy
23,800
+10,900
+84% +$256K ﹤0.01% 7946
2022
Q4 		$297K Buy
+12,900
New +$297K ﹤0.01% 9350
2022
Q2 		– Sell
-10,000
Closed -$189K – 14105
2022
Q1 		$189K Buy
+10,000
New +$194K ﹤0.01% 11606

Other funds holding TMCI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CBU
CIBC Bancorp USA Chicago, Illinois $74.4B AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's TMCI Position: Q1 2026 in Review

Citadel Advisors increased its Treace Medical Concepts (TMCI) stake by 290% in Q1 2026, buying an estimated $1.22M and bringing the position to 825,575 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #7442.

Citadel Advisors first reported a position in TMCI in Q2 2021 and has held it in 19 quarters since. The position peaked at $14.2M in Q1 2023. 118 funds tracked by Wall St. Rank hold TMCI as of Q1 2026.

  • Citadel Advisors held 825,575 shares of Treace Medical Concepts worth $1.11M as of Q1 2026.
  • Citadel Advisors bought 613,669 Treace Medical Concepts shares in Q1 2026, an estimated $1.22M.
  • Treace Medical Concepts made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #7442 holding.
  • Citadel Advisors first reported a position in Treace Medical Concepts in Q2 2021 and has held it in 19 quarters since.
  • Citadel Advisors's Treace Medical Concepts position peaked at $14.2M in Q1 2023.
  • 118 funds tracked by Wall St. Rank held Treace Medical Concepts as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.